Emyria Sees Strong Interest in IBS Study
Released
Released
Announcement PDF
03/12/2020
Emyria sees strong interest in IBS study, launches second drug development program
Highlights:
●
●
●
●
●
●
●
Emyria has received strong interest in its CALM-GUT Study from potential participants
Up to 200 people will be included in the study, expected to last 12 months
Emyria is undertaking this observational study as an important step towards generating evidence
of efficacy and safety for routinely prescribed medicinal cannabis for the management of
symptoms in patients with irritable bowel syndrome (IBS), a significant unmet medical need
This study will also inform the development of EMD-004, Emyria’s second cannabinoid-based drug
candidate
Prof Alistair Vickery and specialist gastroenterologist Dr Chris Schneider are leading the study
across Victoria, NSW and Western Australia
Recruitment is ongoing for this ethics-approved study
Emyria’s managing director, Dr Michael Winlo, will speak on Emyria’s growing product
development portfolio at “TechKnow Invest Perth” on December 8th - registration details below
Emyria Limited (ASX: EMD) (Emyria or the Company), a company that accelerates treatment development
for patients with unmet needs based on its Real-World Evidence (RWE) insights, is pleased to announce
strong interest from potential participants for an Emyria-led study into irritable bowel syndrome (IBS).
IBS affects around 11% of the population globally and is a significant unmet need often associated with
greater levels of anxiety and lower quality of life measures.*
Emyria decided to launch the study following in-depth analysis of it’s Real World Evidence (RWE) data asset
on IBS patients cared for at Emyria’s clinical subsidiary Emerald Clinics (www.emeraldclinics.com.au). The
CALM-GUT study will inform Emyria’s general care program for IBS patients and also Emyria’s second drug
development program to be called EMD-004.
EMD-004 will compliment Emyria’s recent mental health focussed drug development program - EMD-003 which is also backed by Emyria’s RWE (see ASX release 25 NOV 20).
Emyria’s drug development programs encompass unique clinical evidence packages, intellectual property
(IP) and strategically developed clinical trial protocols informed by Emyria’s unique Real-World Evidence
(RWE) and observational trial results. The development programs are intended to support the registration of
specific medicines for specific health indications with the Therapeutic Goods Administration’s (TGA)
Australian Register of Therapeutic Goods (ARTG).
Emyria’s Managing Director, Dr Michael Winlo, said: “We’re pleased to see strong interest in our CALM-GUT
study from patients with irritable bowel syndrome. IBS can be a challenging condition to manage and the
strong interest demonstrates the need for safe and effective options. We were encouraged to initiate this
study based on an analysis of our Real-World Evidence and have designed it to support our second drug
development program - EMD-004. This study will also inform how we can better care for patients with this
condition and we’re very pleased to be collaborating with Dr Chris Schneider, a consultant gastroenterologist
based in Melbourne, on these projects.”
For more details on CALM-GUT, interested potential participants can visit
https://www.emeraldclinics.com.au/clinical-trials
* https://w w w .ncbi.nlm.nih.gov/pmc/articles/PMC3 9 2 1 0 8 3 /
TechKnow Invest
Dr Michael Winlo will present on the company’s product development pipeline and launch strategy at
TechKnow Perth.
Details of the event are as follows:
Event: Techknow Invest Perth
Presenters: Michael Winlo, Managing Director
Time: Tuesday 8th December 2020, 2:00 pm (AWDT)
Where: Ritz Carlton Perth WA
To register to attend in-person (Free): https://tkperth.eventbrite.com.au
To register to the live streaming via zoom (Free), please click through to the link below:
https://techknowperthlivestreaming.eventbrite.com.au
This announcement has been approved and authorised for release by the Board of Emyria Limited.
For further information:
Dr Michael Winlo
Managing Director
(08) 6559 2800
mwinlo@emyria.com
Lexi O’Halloran
Media/Investor Relations
+ 61 (0) 404 577 076
lexi@janemorganmanagement.com.au
About Emyria (www.emyria.com)
Emyria Limited creates drug development programs for patients with unmet needs. These programs can be progressed
by partners or independently. Emyria is uniquely placed to accomplish this by managing an independent specialist
clinical network – Emerald Clinics (www.emeraldclinics.com.au) and by building bespoke remote patient monitoring
technologies and clinical-trial-grade data platforms. Emyria uses these resources to turn its proprietary clinical data
into Real World Evidence (RWE) and unique IP. Emyria’s RWE is the backbone of its patient care and drug development
programs and provides insights into the safety, quality and efficacy of unapproved treatments, in real patients, in the
community. Emyria RWE can greatly accelerate the registration of new treatments. Registered treatments can become
available to a much wider population of patients via routine prescription pathways creating great value. Recently,
Emyria announced the launch of its own drug development program to register new treatments for the growing
challenge of mental health.
Cautionary Note on Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, the company’s
strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and
similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by
such forward-looking statements as a result of various important factors, including: the Company’s ability to
successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability
to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this
press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However, while the Company may elect to update these
forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
These forward-looking statements should not be relied upon as representing the Company’s views as of any date
subsequent to the date hereof.
Share your feedback
Discover